Why does MedTech typically take so much longer to reach a liquidity event than software companies?

The median time to a liquidity event in MedTech commonly runs 8 to 12 years from founding, substantially longer than typical software company timelines, because of the multi-year clinical trial, regulatory clearance or approval, and reimbursement pathway steps that must be completed before meaningful commercial revenue or acquisition interest materializes. This extended timeline is why secondary sales have become an increasingly common partial-liquidity option for long-tenured founders and early employees who might otherwise wait a decade or more for a full exit.

Does a secondary sale of shares count as a liquidity event for purposes of stock option acceleration provisions?

Usually not: many double-trigger vesting acceleration clauses define a qualifying liquidity event narrowly, typically as a company-wide sale or IPO, and generally do not treat an individual secondary transaction between existing stockholders as satisfying that definition. Employees and founders should read their specific option agreement and equity incentive plan language carefully rather than assuming any transaction converting their shares to cash triggers acceleration.

Where does the term liquidity event typically appear in a company's governing documents?

The term commonly appears in vesting acceleration provisions (particularly double-trigger clauses tied to both a liquidity event and a subsequent termination), board approval covenants requiring specific consents before certain transactions, and as a trigger for refreshing a company's 409A valuation given the material change in circumstances a liquidity event typically represents. Understanding how each governing document defines the term precisely matters because the definition is not always uniform across a company's own agreements.

All terms

Investment & FinanceStartup Lifecycle

Liquidity Event

Any transaction that converts illiquid private-company equity into cash or freely tradable securities, typically IPO, M&A, or secondary tender.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 9, 2026

Definition

A liquidity event is any transaction that converts illiquid private-company equity into cash or freely tradable public securities. The three primary forms in MedTech are: an IPO, an acquisition (M&A), or a secondary tender offer in which existing investors (or specialized secondary funds) buy shares from earlier holders. The term often appears in vesting acceleration provisions, board approval covenants, and 409A valuation refresh triggers.

What the regulation says

“Liquidity event” is a financing term, not a single regulatory category. In the United States, the Securities Act of 1933, enacted May 27, 1933, governs securities offerings. Section 5 generally requires registration unless an exemption applies, making registration central to a conventional MedTech IPO. An IPO does not automatically make every existing holder’s shares freely tradable: resale restrictions and contractual lockups may remain. Acquisitions and secondary tenders have different requirements depending on their structure, including applicable securities, tender offer, antitrust, and corporate-law rules. A private secondary sale does not itself make the remaining shares publicly tradable. Tax treatment likewise depends on the instrument and transaction. Internal Revenue Code Section 409A, added by the American Jobs Creation Act of 2004, enacted October 22, 2004, governs certain nonqualified deferred compensation arrangements. Discounted stock options can fall within its scope; a prospective financing or sale may also affect whether an existing equity valuation remains supportable. Not every liquidity event automatically triggers tax or requires a new valuation. Vesting acceleration and investor approval rights generally arise from contractual terms, rather than from a universal regulatory definition of liquidity event.

What this means in practice

MedTech median time to liquidity is significantly longer than software (commonly 8-12 years from founding) due to clinical-trial and regulatory timelines. Secondary transactions have become more common as a partial-liquidity option for long-tenured founders and employees.

Examples

A startup MedTech company develops a novel surgical robot and is acquired by a larger medical device corporation, providing its founders and early investors with a cash payout.
After years of clinical trials and regulatory approvals, a diagnostic MedTech firm successfully completes an Initial Public Offering (IPO), allowing its shares to be traded on a major stock exchange.
Existing venture capital funds in a well-established MedTech company purchase shares from long-term employees and angel investors through a secondary tender offer, providing partial liquidity before an eventual exit.

Common pitfalls

•Assuming a secondary tender qualifies as the 'liquidity event' under double-trigger acceleration clauses, usually it does not.

Frequently asked questions

The three primary liquidity events in MedTech are an initial public offering, an acquisition through M&A, and a secondary tender offer in which existing investors or specialized secondary funds purchase shares directly from earlier stockholders without the company itself being sold or going public. Each form converts illiquid private equity into cash or freely tradable securities, but they differ significantly in scale, timing, and who initiates the transaction.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Investment & Finance

Exit Multiple

Valuation ratio applied at exit, e.g., enterprise value to revenue.

Investment & Finance

Initial Public Offering(IPO)

First sale of a company's stock to public investors via a registered SEC offering, typically on NYSE or Nasdaq.

Investment & Finance

Mergers and Acquisitions(M&A)

Transactions in which one company acquires or combines with another, the dominant MedTech exit path, typically a strategic acquisition by an established player.

Investment & Finance

Vesting Schedule

Timeline over which equity is earned by an employee or founder.

Latest in MedTech

Sources

3 sources

Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 1Binding law and standards· 1Tier 4Trade press and expert commentary· 2

Link health: 3 verified· last checked 2026-06-20

NVCA·1IRS·1SVB·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Investment & Finance0 / 47

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Investment & Finance
Sources: 3
Updated: 5/9/2026

Compare with another term

Learn in 60 seconds

Any transaction that converts illiquid private-company equity into cash or freely tradable securities, typically IPO, M&A, or secondary tender.

·MedTech median time to liquidity is significantly longer than software (commonly 8-12 years from founding) due to clinical-trial and regulatory timelines.
·Secondary transactions have become more common as a partial-liquidity option for long-tenured founders and employees.
·The three primary forms in MedTech are: an IPO, an acquisition (M&A), or a secondary tender offer in which existing investors (or specialized secondary funds) buy shares from earlier holders.

Remember this

Watch out: Assuming a secondary tender qualifies as the 'liquidity event' under double-trigger acceleration clauses, usually it does not.

Related terms

You may also need

Auto-suggested from Investment & Finance and shared keywords.

All Investment & Finance terms

Definition

What this means in practice

Examples

Frequently asked questions

Related terms

Editor's picks

More in Investment & Finance

Latest in MedTech

Sources